Search Results - "Ahmed, Sherihan Rezk"
-
1
Predictors of the unfavorable outcomes in acute ischemic stroke patients treated with alteplase, a multi-center randomized trial
Published in Scientific reports (12-03-2024)“…Worldwide, stroke is a leading cause of long-term disability in adults. Alteplase is the only approved treatment for acute ischemic stroke (AIS) and results in…”
Get full text
Journal Article -
2
Evaluation of dysphagia in different phenotypes of early and idiopathic Parkinsonism
Published in The Egyptian Journal of Neurology, Psychiatry and Neurosurgery (24-10-2018)“…Parkinsonism (PD) is a common neurodegenerative disorders into which dysphagia occurs mainly in the late stage and to a lesser extent in an early stage…”
Get full text
Journal Article -
3
Ticagrelor Versus Clopidogrel in Acute Large-Vessel Ischemic Stroke: A Randomized Controlled Single-Blinded Trial
Published in CNS drugs (01-05-2024)“…Background Large-vessel ischemic stroke represents about 25–40% of all ischemic strokes. Few clinical trials compared ticagrelor versus clopidogrel in ischemic…”
Get full text
Journal Article -
4
Association of white matter hyperintensities with migraine phenotypes and response to treatment
Published in Acta neurologica Belgica (01-10-2023)“…Introduction White matter hyperintensities (WMHs) are frequently found in migraineurs. However, their clinical significance and correlation to different…”
Get full text
Journal Article -
5
TICA-CLOP STUDY: Ticagrelor Versus Clopidogrel in Acute Moderate and Moderate-to-Severe Ischemic Stroke, a Randomized Controlled Multi-Center Trial
Published in CNS drugs (09-11-2024)“…Many studies evaluated the efficacy and safety of ticagrelor versus clopidogrel in patients with ischemic stroke; none of these trials included North African…”
Get full text
Journal Article -
6
The effect of lacosamide on calcitonin gene-related peptide serum level in episodic migraine patients: a randomized, controlled trial
Published in Acta neurologica Belgica (01-06-2024)“…Background Migraine affects 11–15% of people worldwide, and the calcitonin gene-related peptide (CGRP) is released during the migraine attack, producing…”
Get full text
Journal Article